SCHEMBL21113010

SCHEMBL21113010

O=C(OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O)c1cccc(Oc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.45
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HK1 P19367 1/20 0.42
HK2 P52789 1/20 0.42
TYMP P19971 1/20 0.42
NPC1 O15118 1/20 0.41
SLC5A2 P31639 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TNKS O95271 1/20 0.41
PARP15 Q460N3 1/20 0.41
PARP14 Q460N5 1/20 0.41
PARP10 Q53GL7 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
PARP2 Q9UGN5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21112887 0.89 SMN1; SMN2 (0.50) HK1HK2ALDH1A1PARP10TDP1
SCHEMBL21112880 0.88 MEN1 (0.43) AKR1C3MEN1MAPTKMT2APOLB
SCHEMBL15562678 0.87 HK1 (0.43) HK1HK2TYMPALDH1A1TDP1
SCHEMBL15562680 0.87 HK1 (0.43) HK1HK2TYMPALDH1A1TDP1
SCHEMBL21112881 0.86 TDP1 (0.48) AKR1C3MEN1MAPTKMT2APOLB
SCHEMBL9245472 0.86 ALDH1A1 (0.49) POLBHK1HK2TYMPALDH1A1
SCHEMBL26455064 0.86 ALDH1A1 (0.49) POLBHK1HK2TYMPALDH1A1
SCHEMBL9245476 0.86 ALDH1A1 (0.49) POLBHK1HK2TYMPALDH1A1
SCHEMBL15562679 0.85 HK1 (0.46) HK1HK2TYMPALDH1A1TDP1
SCHEMBL21112929 0.83 MEN1 (0.40) AKR1C3MEN1MAPTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 US disclosed
CN-109562185-A Novel conjugates of agents and moieties capable of binding to glucose-sensing proteins 赛诺菲 2019-04-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 AKR1C3 1463/4885MEN1 1610/4885MAPT 3717/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 AKR1C3 1463/4885MEN1 1610/4885MAPT 3717/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 AKR1C3 1463/4885MEN1 1610/4885MAPT 3717/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 AKR1C3 1463/4885MEN1 1610/4885MAPT 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.